000			03695nam a22004097a 4500
008			230411s20232023 xxu||||| |||| 00| 0 eng d
022			_a0735-6757
024			_a10.1016/j.ajem.2023.03.025 [doi]
024			_aS0735-6757(23)00140-7 [pii]
040			_aOvid MEDLINE(R)
099			_a36965470
245			_aCyclobenzaprine utilization for musculoskeletal back pain, analysis of 2007-2019 National Hospital Ambulatory Medical Care Survey Data.
251			_aAmerican Journal of Emergency Medicine. 68:106-111, 2023 Mar 18.
252			_aAm J Emerg Med. 68:106-111, 2023 Mar 18.
253			_aThe American journal of emergency medicine
260			_c2023
260			_fFY2023
260			_p2023 Mar 18
265			_saheadofprint
265			_tPublisher
266			_d2023-04-11
501			_aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
520			_aBACKGROUND: With musculoskeletal back pain being one of the most common presentations in the emergency department, evidence-based management strategies are needed to address such complaints. Along with other medications, cyclobenzaprine is a muscle relaxant commonly prescribed for patients complaining of musculoskeletal pain, in particular, pain associated with muscle spasms. However, with recent literature questioning its efficacy, the role of cyclobenzaprine use in patients with musculoskeletal back pain remains unclear.
520			_aCONCLUSIONS: Although there was a slight decrease, our study still shows significant cyclobenzaprine utilization in the ED, despite conflicting evidence demonstrating efficacy for patients with musculoskeletal complaints and the concern for adverse effects. Additional studies are needed to examine its overall effectiveness and risk-benefit analysis in treating patients with such conditions. Copyright © 2023 Elsevier Inc. All rights reserved.
520			_aMETHODS: This is a retrospective cohort review of data obtained from the National Hospital Ambulatory Medical Care Survey (NHAMCS) between 2007 and 2019. We analyzed ED visits of patients 18 years and older. Visits during which cyclobenzaprine was administered in the ED or prescribed at discharge were identified. Trends were described using a time series analysis of patients' visits who received administration and prescriptions of cyclobenzaprine.
520			_aOBJECTIVES: The objective of the study is to investigate trends of cyclobenzaprine utilization among patients presenting to the emergency department (ED) in the United States.
520			_aRESULTS: Between 2007 and 2019, we identified an estimated 1.35 billion ED visits, 57.2% (772.6 million) were female. From that sample, 2.4% (32.7 million) of all visits received cyclobenzaprine prescription in the ED only, and 0.5% (6.6 million) of total visits were both given the drug in the ED and were prescribed the drug at discharge). Overall trend analysis shows a slight decrease in annual percentages of cyclobenzaprine administration and prescriptions during the study period. Visits of certain subgroups: 26-44 years, white showed relatively higher percentages of administration and prescription of cyclobenzaprine.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aEmergency Medicine
657			_aJournal Article
700			_aMazer-Amirshahi, Maryann _bMWHC
790			_aPourmand A, AlRemeithi R, Martinez S, Couperus C, Mazer-Amirshahi M, Yang J, Tran QK
856			_uhttps://dx.doi.org/10.1016/j.ajem.2023.03.025 _zhttps://dx.doi.org/10.1016/j.ajem.2023.03.025
942			_cART _dArticle
999			_c11572 _d11572